The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
| Autor: | Ilnaz Zohrabi, Elham Maraghi, Gholamreza Houshmand, Parvin Abedi, Somayeh Ansari, Nader Shakiba Maram |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Vaginal Diseases Reproductive medicine Iran Placebo Oxytocin lcsh:Gynecology and obstetrics law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Double-Blind Method law medicine Humans 030212 general & internal medicine Contraindication Vaginal atrophy lcsh:RG1-991 Aged 030219 obstetrics & reproductive medicine Obstetrics business.industry lcsh:Public aspects of medicine Obstetrics and Gynecology lcsh:RA1-1270 General Medicine Middle Aged medicine.disease Postmenopausal women Postmenopause Administration Intravaginal medicine.anatomical_structure Treatment Outcome Reproductive Medicine Vagina Vaginal Creams Foams and Jellies Female Hormone therapy Atrophy business medicine.drug Research Article |
| Zdroj: | BMC Women's Health, Vol 20, Iss 1, Pp 1-7 (2020) BMC Women's Health |
| DOI: | 10.21203/rs.2.13815/v2 |
| Popis: | Background Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. Methods This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40–60, at least 1 year passed from their last menstrual period or the level of FSH > 40 IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention. Results The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7 ± 7.18 vs. 3.69 ± 2.76, p = 0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76 ± 4.68 to 52.48 ± 7.54) in comparison to the placebo group (increased from 8.58 ± 4.35 to 13.25 ± 5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p = 0.0001). After 8 weeks, 88.6 and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p = 0.001). Conclusion The results of this study showed that eight- week intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended. Trial registration IRCT20160602028220N2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|